E-LIB Suche - Ergebnisse für: Morcos, Peter N

1

Population pharmacokinetics of imetelstat, a first‐in‐class..:

González‐Sales, Mario ; Lennox, Ashley L. ; Huang, Fei...
CPT: Pharmacometrics & Systems Pharmacology. 13 (2024) 7 - p. 1264-1277 , 2024

Link: https://doi.org/10.1002/..

2

CHRONOS-4: Phase 3 study of copanlisib plus rituximab-based..:

Zinzani, Pier Luigi Luigi ; Wang, Huaqing ; Feng, Jifeng...
Blood Advances. , 2024

Link: https://doi.org/10.1182/..

3

Model‐Based Benefit/Risk Analysis for the Copanlisib Interm..:

Morcos, Peter N. ; Moss, Jonathan ; Veasy, Josh...
Clinical Pharmacology & Therapeutics. 115 (2024) 5 - p. 1092-1104 , 2024

Link: https://doi.org/10.1002/..

4

Model‐informed approach to support pediatric dosing for the..:

Morcos, Peter N. ; Schlender, Jan ; Burghaus, Rolf...
Clinical and Translational Science. 16 (2023) 7 - p. 1197-1209 , 2023

Link: https://doi.org/10.1111/..

5

Copanlisib population pharmacokinetics from phase I–III stu..:

Morcos, Peter N. ; Moss, Jonathan ; Austin, Rupert...
CPT: Pharmacometrics & Systems Pharmacology. 12 (2023) 11 - p. 1666-1686 , 2023

Link: https://doi.org/10.1002/..

6

Circulating Cell-free DNA as a Prognostic Biomarker in Pati..:

Dziadziuszko, Rafal ; Peters, Solange ; Mok, Tony...
Clinical Cancer Research. 28 (2022) 9 - p. 1800-1808 , 2022

Link: https://doi.org/10.1158/..

7

Quantitative Clinical Pharmacology Supports the Bridging Fr..:

Jamois, Candice ; Gibiansky, Ekaterina ; Gibiansky, Leonid...
Clinical Pharmacology & Therapeutics. 110 (2021) 5 - p. 1261-1272 , 2021

Link: https://doi.org/10.1002/..

8

Pharmacometric analyses of alectinib to facilitate approval..:

Hsu, Joy C. ; Jaminion, Felix ; Guerini, Elena...
CPT: Pharmacometrics & Systems Pharmacology. 10 (2021) 11 - p. 1357-1370 , 2021

Link: https://doi.org/10.1002/..

9

Assessing the translational value of pre-clinical studies f..:

Liu, Wenying Angela ; Yu, Li ; Morcos, Peter N...
Cancer Chemotherapy and Pharmacology. 85 (2020) 6 - p. 1015-1027 , 2020

Link: https://doi.org/10.1007/..

10

Quantitative Clinical Pharmacology of T‐Cell Engaging Bispe..:

Morcos, Peter N. ; Li, Junyi ; Hosseini, Iraj.
Clinical and Translational Science. 14 (2020) 1 - p. 75-85 , 2020

Link: https://doi.org/10.1111/..

11

Pooled overall survival and safety data from the pivotal ph..:

Ou, Sai-Hong Ignatius ; Gadgeel, Shirish M. ; Barlesi, Fabrice...
Lung Cancer. 139 (2020) - p. 22-27 , 2020

Link: https://doi.org/10.1016/..

12

Model‐Informed Drug Development Approach to Expedite Approv..:

Morcos, Peter N. ; Liu, Jiang ; Blumenthal, Gideon M..
Clinical Pharmacology & Therapeutics. 105 (2019) 4 - p. 826-828 , 2019

Link: https://doi.org/10.1002/..

13

Rituximab dosing in hematological malignancies: an old ques..:

Morcos, Peter N. ; Boehnke, Axel ; Valente, Nancy.
Cancer Chemotherapy and Pharmacology. 84 (2019) 3 - p. 661-666 , 2019

Link: https://doi.org/10.1007/..

14

Exposure–response analysis of alectinib in crizotinib-resis..:

Morcos, Peter N. ; Nueesch, Eveline ; Jaminion, Felix...
Cancer Chemotherapy and Pharmacology. 82 (2018) 1 - p. 129-138 , 2018

Link: https://doi.org/10.1007/..

15

Effect of Hepatic Impairment on the Pharmacokinetics of Ale..:

Morcos, Peter N. ; Cleary, Yumi ; Sturm‐Pellanda, Carolina...
The Journal of Clinical Pharmacology. 58 (2018) 12 - p. 1618-1628 , 2018

Link: https://doi.org/10.1002/..